Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphoproliferative disorders

D Catovsky1

  • 1Royal Marsden Hospital, London, UK.

Current Opinion in Oncology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Advances in diagnosing and treating chronic lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL) and hairy-cell leukemia (HCL), have been significant. New diagnostic methods and nucleoside analogue treatments have greatly improved remission rates and survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.

Nature genetics·1997
Same author

The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia.

Leukemia·1997
Same author

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.

British journal of haematology·1997
Same author

G-CSF mobilization of haemopoietic cell populations in SCID mice engrafted with human leukaemia.

Bone marrow transplantation·1997
Same author

Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia?

Leukemia·1997
Same author

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1997
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphoproliferative disorders (CLPDs) encompass a group of hematologic malignancies.
  • Significant progress has been made in understanding and managing specific CLPDs.

Purpose of the Study:

  • To highlight recent advances in the diagnosis and treatment of CLPDs.
  • To discuss the impact of new diagnostic tools and therapeutic agents on patient outcomes.

Main Methods:

  • Improved diagnostic techniques including cell morphology and monoclonal antibody use.
  • Application of nucleoside analogues as therapeutic agents.

Main Results:

  • Enhanced diagnostic specificity for chronic lymphocytic leukemia (CLL) and hairy-cell leukemia (HCL) through combined morphology and immunophenotype.

Related Experiment Videos

  • Characterization of splenic lymphoma with villous lymphocytes as a distinct entity.
  • Significant improvements in remission rates and disease-free survival for CLL and HCL using nucleoside analogues like fludarabine, deoxycoformycin, and chlorodeoxyadenosine.
  • Continued research into adult T-cell leukemia-lymphoma and its causative retrovirus, human T-cell lymphotropic virus I (HTLV-I).

    • Conclusions:

    • Advances in diagnostics and therapeutics have substantially improved the management of CLPDs.
    • Nucleoside analogues represent a major breakthrough in treating CLL and HCL.
    • Further research on HTLV-I is crucial for understanding and preventing adult T-cell leukemia-lymphoma.